CN Stock MarketDetailed Quotes

600557 Jiangsu Kanion Pharmaceutical

Watchlist
  • 15.68
  • -0.56-3.45%
Noon Break Jul 23 11:29 CST
9.12BMarket Cap16.79P/E (TTM)

Jiangsu Kanion Pharmaceutical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Jiangsu Kanion Pharmaceutical Earnings Date

Currency: CNY

Period

Q1 FY2024 Earnings

Apr 13, 2024

Revenue(YoY)

1.36B

+0.48%
EPS(YoY)

0.25

+4.17%
Analyst Rating

Strong Buy

Jul 23, 2024

Jiangsu Kanion Pharmaceutical Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: CNY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q3-- / 1.065B--
Jul 27, 20242024/Q2-- / 1.357B--
Apr 13, 20242024/Q11.359B / 1.528B--
Mar 11, 20242023/Q41.372B / 1.377B--
Oct 26, 20232023/Q3942.863M / 1.282B--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q3-- / 1.065B--
Jul 27, 20242024/Q2-- / 1.357B--
Apr 13, 20242024/Q11.359B / 1.528B--
Mar 11, 20242023/Q41.372B / 1.377B--
Oct 26, 20232023/Q3942.863M / 1.282B--

Unlock Free Earnings Estimates

Jiangsu Kanion Pharmaceutical Earnings Reports

  • Jiangsu Kangyuan Pharmaceutical Co., Ltd. Report for the first quarter of 2024

    Apr 12 12:00 ET

  • Jiangsu Kangyuan Pharmaceutical Co., Ltd. 2023 Annual Report

    Mar 10 12:00 ET

  • Summary of the 2023 Annual Report of Jiangsu Kangyuan Pharmaceutical Co., Ltd.

    Mar 10 12:00 ET

  • Jiangsu Kangyuan Pharmaceutical Co., Ltd. Report for the Third Quarter of 2023

    Oct 25, 2023 12:00 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Jul 23, 2024

    Strong Buy

    • Strong Buy

      76.19%

    • Buy

      23.81%

    • Hold

      0.00%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    CN
    Overall
    Symbol
    Latest Price
    %Chg